Roche Exits Insulin Pumps Segment In India
Roche Diagnostics has exited the insulin pumps segment in India, but the Swiss multinational says it stays focused on the self-monitoring solutions segment for diabetics in a country that has more than 69 million people living with the chronic disease.
You may also be interested in...
Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.
Roche's diabetes business continues to struggle as third quarter results show sales in the division dipped by 3%, while Quest Diagnostics' bottom line took a hit from special charges. Meanwhile, bioMérieux said third-quarter revenues increased by 7%; Danaher is finalizing its acquisition of Cepheid.
Despite caution over emerging markets turmoil and a possible slowdown at the time of its third quarter results, in the end 2015 turned out well for Roche, with its pharma sales in key market China regaining momentum on the back of product expansions and oncology access schemes.